Clinicians sorely need new treatment approaches for glioblastoma, the most aggressive form of brain cancer.
The blood-brain barrier—a protective sheath separating brain tissue from its blood vessels—makes it difficult to attack the disease with drugs. It's also difficult to completely remove through surgery, as even tiny remnants inevitably spawn new tumors, Ken Kingery writes.
Even with the best care currently available, median survival time is a dire 15 months, and only 10 percent of patients survive five years once diagnosed.
The Duke team decided to pursue an aggressive treatment option to match its opponent, turning to the bacterium Salmonella typhimurium. With a few genetic tweaks, the engineers turned the bacterium into a cancer-seeking missile that produces self-destruct orders deep within tumors.
Tests in rat models with extreme cases of the disease showed a remarkable 20 percent survival rate over 100 days—roughly equivalent to 10 human years—with the tumors going into complete remission.
Previous studies have shown, quite accidentally, that the presence of bacteria can cause the immune system to recognize and begin attacking tumors. However, follow-up clinical trials with genetically detoxified strains of S. typhimurium have since proven ineffective by themselves.
To use these common intestinal bacteria as tumor-seeking missiles, Lyon and Bellamkonda, working with lead co-author Nalini Mehta, selected a detoxified strain of S. typhimurium that was also deficient in a crucial enzyme called purine, forcing the bacteria to seek supplies elsewhere.
Tumors just so happen to be an excellent source of purine, causing the bacteria to flock to them in droves.
Then, the Duke engineers made a series of genetic tweaks so that the bacteria would produce two compounds called Azurin and p53 that instruct cells to commit suicide—but only in the presence of low levels of oxygen. And since cancerous cells are multiplying so energetically, the environment around and within tumors has unusually low oxygen.
The researchers tested the modified bacteria by injecting them directly into the rats' brains. While this may sound like an extreme delivery option, the first course of action usually performed with glioblastoma is to surgically remove the primary tumor, if possible, leaving the opportunity to directly deliver therapeutics.
The treatment worked in 20 percent of the rats, causing complete tumor regression and extending their lives by 100 days, which translates to roughly 10 human years.
In the 80 percent that did not survive, however, the treatment didn't change the length of time the rats survived.
After testing for common signs of resistance to the anti-tumor compounds and finding none, the researchers concluded the ineffectiveness was likely due to inconsistencies in the bacteria's penetration, or to the aggressive tumor growth outpacing the bacteria. But every rat showed initial signs of improvement after treatment. ■
What to read next
More inside POST
Atomic superyacht for all oceans and seas Sea, Land, Air